Atopic Dermatitis (AD)
75
19
26
30
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
2.7%
2 terminated out of 75 trials
93.8%
+7.2% vs benchmark
20%
15 trials in Phase 3/4
20%
6 of 30 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 30 completed trials
Clinical Trials (75)
Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Reflectance Confocal Microscopy Evaluation of Skin Structure of Patients With Atopic Dermatitis Under Nemolizumab
Topical Chinese Medicine and Exosome Mechanisms for Atopic Dermatitis
The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
Global Healthcare Study on Atopic Dermatitis
Clinical Trial of an Ointment in Patients With Mild and Moderate Atopic Dermatitis
A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis
Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection
A Study on the Efficacy of 2% Cholesterol Cream in Atopic Dermatitis
Evaluation by Confocal Reflectance Microscopy of the Skin Structure of Patients With Atopic Dermatitis Treated With Tralokinumab Biotherapy.
The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World Study
Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis